Michael T. Spiotto

Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (4)

Purpose Sleep-related symptom prevalence is not well-characterized and likely under-recognized in head and neck cancer. We investigated longitudinal symptom severity trajectory, prevalence of moderate/severe symptoms, and association between severe sleep-related patient-reported symptoms and oncologic endpoints in oropharyngeal cancer (OPC) patients receiving radiotherapy (RT). Methods A longitudinal cohort of 372 patients with OPC treated with curative-intent RT with/without chemotherapy at a single-site tertiary center was queried at RT start, end of RT, and six months post-RT. All completed baseline MD Anderson Symptom Inventory-Head and Neck (MDASI-HN) at start of RT. Sleep-related symptom items included “fatigue”, “disturbed sleep”, and “drowsiness” (mild, moderate, severe). Clinical data were collected, and overall survival (OS) was evaluated using Kaplan-Meier/log-rank tests and multivariable Cox proportional hazards models with covariate adjustment. Results Severe fatigue, disturbed sleep, and drowsiness were infrequent at baseline and at RT start, but peaked at RT end (26%, 15% and 18%) and returned to near-baseline prevalence by six months after RT (6%, 4%, 2%). In Cox proportional hazard models, severe longitudinal fatigue (HR 5.05, 95% CI 1.25-17.07, p = 0.013), sleep (HR 3.86, 95% CI 1.23 to 10.16, p = 0.0104), and drowsiness burden (HR 8.24, 95% CI 1.22 to 32.62, p = 0.008) were all independently associated with worse OS. Additionally, severe fatigue (HR = 3.58, 95% CI: 1.09 to 10.11, p = 0.0375), sleep disturbance (HR 5.08, 95% CI 1.60-13.51, p = 0.0081), and drowsiness (HR=7.76, 95% CI 1.45-33.47, p=0.0193) reported at RT start were also independently associated with significantly worse OS. Aside from age, severe average daily symptom scores, and severe symptoms reported at RT start, were independently associated with worse OS. Conclusion Severe sleep related symptoms were uncommon at baseline or RT start, but a substantial proportion of OPC patients experienced clinically meaningful sleep disturbances by the end of RT. At an average follow up of 84 months, severe longitudinal fatigue, sleep, and drowsiness burden were all independently associated with worse OS in OPC. Severe fatigue, drowsiness and sleep disturbance reported at RT start were also independently associated with worse OS. Assessment of sleep disturbances along with potential physiologic correlates are an important part of comprehensive care.

Year:

2025

Objective Patient-reported outcomes (PROs) contain valuable information that can be leveraged by providers to perform timely interventions and improve quality of life and survival. However, the implementation of electronic PROs (ePROs) remains a challenge from technical, behavioral, and evaluation perspectives. Our objective was to construct a robust electronic health record (EHR)-integrated ePRO information infrastructure founded on RE-AIM (Reach-Effectiveness-Adoption-Implementation-Maintenance) principles. Materials and Methods We used Epic Systems as our EHR platform to build the MD Anderson Symptom Index-Head and Neck Module (MDASI-HN) for release to all patients undergoing evaluation and/or treatment in our HN Radiation Oncology clinics. RE-AIM metrics were established and used to design patient-, provider-, and implementing facilitator information tools. Results From January 2021 to July 2024, our ePRO program has collected 13,156 patient-submitted ePROs on 3,497 unique HN patients, with a 12-month sustained ePRO compliance rate of 82%. We also propose a dynamic clinical implementation-evaluation cycle. This model can be used to continuously (re)define, build, and adapt ePRO information tools for patients, providers, and program facilitators. Discussion Our ePRO framework has several benefits including integrated clinical data for enhanced decision-making, potential scalability, and use of a common EHR system. Formative (i.e., mid-phase) evaluation and feedback were essential in our program, allowing for timely optimization of ePRO compliance, ePRO usage by clinical staff, and secondary use of high-quality ePRO data. Conclusion In this article, we provide a valuable roadmap towards developing a comprehensive, EHR-based ePRO information infrastructure simultaneously optimized for clinical utility and implementation evaluation founded on RE-AIM principles.

Year:

2025

Background Existing studies on osteoradionecrosis of the jaw (ORNJ) have primarily used cross-sectional data, assessing risk factors at a single time point. Determining the time-to-event profile of ORNJ has important implications to monitor oral health in head and neck cancer (HNC) long-term survivors. Methods Demographic, clinical and dosimetric data were retrospectively obtained for a clinical observational cohort of 1129 patients with HNC treated with radiotherapy (RT) at The University of Texas MD Anderson Cancer Center. ORNJ was diagnosed in 198 patients (18%). A multivariable logistic regression analysis with forward stepwise variable selection identified significant predictors for ORNJ. These predictors were then used to train a Weibull Accelerated Failure Time (AFT) model, which was externally validated using an independent cohort of 265 patients (92 ORNJ cases and 173 controls) treated at Guy’s and St. Thomas’ Hospitals. Findings Our model identified that each unit increase in D25% is significantly associated with a 12% shorter time to ORNJ (Adjusted Time Ratio [ATR] 0·88, p<0·005); pre-RT dental extractions was associated to a 27% faster (ATR 0·73, p=0·13) onset of ORNJ; male patients experienced a 38% shorter time to ORNJ (ATR 0·62, p = 0·11). The model demonstrated strong internal calibration (integrated Brier score of 0·133, D-calibration p-value 0.998) and optimal discrimination at 72 months (Harrell’s C-index of 0·72). The model also showed good generalization to the independent cohort, despite a slight drop in performance. Interpretation This study is the first to demonstrate a direct relationship between radiation dose and the time to ORNJ onset, providing a novel characterization of the impact of delivered dose not only on the probability of a late effect (ORNJ), but the conditional risk during survivorship. Funding This work was supported by various funding sources including NIH, NIDCR, NCI, NAPT, NASA, BCM, Affirmed Pharma, CRUK, KWF Dutch Cancer Society, NWO ZonMw, and the Apache Corporation.

Year:

2024

Background Recently, randomized trials have questioned the efficacy of cetuximab‐based bioradiotherapy compared to chemoradiation for patients with squamous cell carcinoma of the oropharynx, larynx, and hypopharynx (HNSCC). We compared the OS of patients treated with radiotherapy alone (RTonly), chemoradiotherapy (chemoRT), and bioradiotherapy (cetuxRT). Methods Patients with stage III–IVB HNSCC treated with RTonly, chemoRT, or cetuxRT were identified in the National Cancer Database. OS was estimated using Cox proportional hazards. Analyses were conducted on the overall cohort and propensity matched cohorts. Results 31 014 patients were treated with RTonly (22%), chemoRT (72%), or cetuxRT (6%) from 2013 to 2016. The 2‐year OS was 69% for RTonly, 79% for chemoRT, and 66% for cetuxRT ( p < 0.001). In the overall and propensity‐matched cohorts, chemoRT and RTonly were associated with improved OS as compared to cetuxRT ( p ≤ 0.001). Conclusion Compared to chemoRT or RTonly, cetuxRT is associated with decreased OS for patients with HNSCC, suggesting minimal benefit of bioradiotherapy in this population.

Year:

2022

Collaborators (24)

Anna Lee

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Steven Frank

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Lisanne van Dijk

Associate professor & Technical physician

University Medical Center Groningen

NETHERLANDS
View details

Katherine Hutcheson

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Natalie West

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Saadia Faiz

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Jack Phan

Physician/Associate Professor

MD Anderson Cancer Center

UNITED STATES
View details

Seyedmohammadhossein Hosseinian

Assistant Professor

North Carolina State University

UNITED STATES
View details

Vlad Sandulache

Associate Professor

Baylor College of Medicine

UNITED STATES
View details

Stephen Lai

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Amy Moreno

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

David Rosenthal

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Guadalupe Canahuate

The University of Iowa

UNITED STATES
View details

Andrew Schaefer

Professor

Rice University

UNITED STATES
View details

Miriam Lango

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Teresa Guerrero Urbano

Adjunct Reader

King's College London

UNITED KINGDOM
View details

Mark Chambers

Professor & Deputy Chair/Medical Director, Section of Oral Oncology and Maxillofacial Prosthodontics

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Jillian Rigert

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Melissa Chen

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

G.E. Marai

-

UNITED STATES
View details

Mohamed Naser

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Abdallah Mohamed

Assistant Professor

Baylor College of Medicine

UNITED STATES
View details

Zaphanlene Kaffey

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Clifton D Fuller

Professor (Tenured)

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details